Prolonged Exposure to Caplacizumab as Rescue Therapy in Refractory Immune Thrombotic Thrombocytopenic Purpura

Abstract

George M Rodgers,1 Misa Berndt,2 Megan Fonteno,3 Jeffrey A Gilreath2,4 1Division of Hematology and Hematologic Malignancies Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA; 2Sugarhouse Hematology, University of Utah, Salt Lake City, UT, USA; 3Clinical Pharmacy, MD Anderson Cancer Institute, Houston, TX, USA; 4Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USACorrespondence: George M Rodgers, Division of Hematology and Hematologic Malignancies, University of Utah Medical Center, Salt Lake City, UT, 84132, USA, Tel [phone], Email [email protected]: We describe a case of refractory thrombotic thrombocytopenic purpura (7 lines of therapy) in which caplacizumab was used over a 6-month period as rescue therapy. Caplacizumab maintained the patient in clinical remission until successful immunosuppression was achieved resulting in normal ADAMTS13 levels. This case illustrates the utility of caplacizumab therapy in treating refractory TTP.Keywords: thrombotic thrombocytopenic purpura, caplac izumab, ADAMTS13, von Willebrand factor

Keywords

• thrombotic thrombocytopenic purpura
• caplacizumab
• adamts13
• von willebrand factor.